Dichoptic Virtual Reality Therapy for Amblyopia in Adults
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Sep 18, 2014
Trial Information
Current as of April 30, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Interpupillary distance of 60-66 mm
- • Age 15-40
- • Anisometropic amblyopia or strabismic amblyopia
- • Best corrected visual acuity of 20/30 or worse in the amblyopic eye
- • No prior therapeutic use of the software
- • No other ongoing therapies including patching or recent eye muscle surgery
- • No vested interest in the product
- • Ability attend visits and complete the training session, and to stop the intervention after the specified intervention period
- Exclusion Criteria:
- • Stimulus-deprivation amblyopia.
- • Organic lesions of the eye preventing the establishment of good vision (eg. media opacities, abnormalities in the fundus or optic nerve).
- • Lesions of the brain preventing the establishment of good vision (eg. cortical visual impairment).
- • Establishment of normal vision by refractive adaptation (wearing glasses after presentation).
- • Patients diagnosed with Photosensitive Epilepsy.
- • Inability to comply with the follow-up visits required.
- • History of pathologic nystagmus (congenital or sensory).
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
San Francisco, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials